CA2156512A1 - Treatment of androgen-associated baldness using antisense oligomers - Google Patents

Treatment of androgen-associated baldness using antisense oligomers

Info

Publication number
CA2156512A1
CA2156512A1 CA002156512A CA2156512A CA2156512A1 CA 2156512 A1 CA2156512 A1 CA 2156512A1 CA 002156512 A CA002156512 A CA 002156512A CA 2156512 A CA2156512 A CA 2156512A CA 2156512 A1 CA2156512 A1 CA 2156512A1
Authority
CA
Canada
Prior art keywords
androgen
baldness
treatment
antisense oligomers
oligomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002156512A
Other languages
French (fr)
Other versions
CA2156512C (en
Inventor
Mary Ellen Harper
Tod Mitchell Woolf
Lyle John Arnold Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2156512A1 publication Critical patent/CA2156512A1/en
Application granted granted Critical
Publication of CA2156512C publication Critical patent/CA2156512C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/99—Oxidoreductases acting on the CH-CH group of donors (1.3) with other acceptors (1.3.99)
    • C12Y103/99005—3-Oxo-5alpha-steroid 4-dehydrogenase (acceptor) (1.3.99.5), i.e. steroid-5alpha-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of treating androgen-associated hair loss, in particular decreasing the progression of male pattern baldness using nucleoside Oligomers and Oligomers useful in the described methods are provided.
CA002156512A 1993-02-19 1994-02-18 Treatment of androgen-associated baldness using antisense oligomers Expired - Fee Related CA2156512C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1954393A 1993-02-19 1993-02-19
US08/019,543 1993-02-19
PCT/US1994/001748 WO1994018835A1 (en) 1993-02-19 1994-02-18 Treatment of androgen-associated baldness using antisense oligomers

Publications (2)

Publication Number Publication Date
CA2156512A1 true CA2156512A1 (en) 1994-09-01
CA2156512C CA2156512C (en) 2002-11-19

Family

ID=21793773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002156512A Expired - Fee Related CA2156512C (en) 1993-02-19 1994-02-18 Treatment of androgen-associated baldness using antisense oligomers

Country Status (6)

Country Link
EP (1) EP0684764A4 (en)
JP (1) JPH08506961A (en)
AU (1) AU692148B2 (en)
CA (1) CA2156512C (en)
IL (1) IL108712A0 (en)
WO (1) WO1994018835A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739553B1 (en) * 1995-10-06 1998-01-02 Oreal USE OF BRADYKININE ANTAGONISTS TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP THE HAIR LOSS
AU2666797A (en) * 1996-04-15 1997-11-07 Dyad Pharmaceutical Corporation Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
US6489163B1 (en) * 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6841539B1 (en) * 1998-05-21 2005-01-11 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US20020086387A1 (en) * 2000-04-13 2002-07-04 Rachel Meyers 23155 novel protein human 5-alpha reductases and uses therefor
IT1318379B1 (en) * 2000-03-08 2003-08-25 Ira Srl COSMETIC OR PHARMACEUTICAL COMPOSITION USEFUL TO INHIBIT OR DELAY HUMAN ALOPECIA THROUGH TOPICAL APPLICATION OF THE COMPOSITION.
FR2832154B1 (en) 2001-11-09 2007-03-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE
WO2005042741A2 (en) * 2003-10-21 2005-05-12 Dyad Pharmaceutical Corporation METHODS AND COMPOSITIONS FOR TREATING 5alpha-REDUCTASE TYPE 1 AND TYPE 2 DEPENDENT CONDITIONS
DE102004025881A1 (en) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonucleotides for influencing hair growth
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
JP6768253B2 (en) * 2015-10-09 2020-10-14 井上　肇 How to get information about androgenetic alopecia in the subject
CA3032549A1 (en) * 2016-08-08 2018-02-15 Olipass Corporation Androgen receptor antisense oligonucleotides
CN110248956B (en) * 2016-10-11 2023-02-21 奥利通公司 HIF-1 alpha antisense oligonucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101978A0 (en) * 1991-05-31 1992-12-30 Genta Inc Neutral oligomers capable of being delivered transdermally and across mucous membranes
IL107934A0 (en) * 1992-12-08 1994-04-12 Genta Inc Formation of triple helix complexes

Also Published As

Publication number Publication date
CA2156512C (en) 2002-11-19
IL108712A0 (en) 1994-05-30
EP0684764A4 (en) 1997-10-22
AU6243794A (en) 1994-09-14
JPH08506961A (en) 1996-07-30
EP0684764A1 (en) 1995-12-06
AU692148B2 (en) 1998-06-04
WO1994018835A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
CA2156512A1 (en) Treatment of androgen-associated baldness using antisense oligomers
CA2170016A1 (en) Improved method for treating hair loss
AU5531596A (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
AU654129B2 (en) Catalysts and processes useful in producing 1,3-diols and/or 3-hydroxyaldehydes
EP0718325A3 (en) Process for preparing ethylene-alpha-olefin-nonconjugated polyene random copolymer, copolymer obtained thereby, and uses of the copolymer
GB9506926D0 (en) Cystine-siicone copolymers and their use for treating keratin substrates
AU1108695A (en) Aza-4-iminoquinolines, methods of preparing them and their use
ZA93226B (en) Abrasive articles including a crosslinked siloxane, and methods of making and using same.
ZA927277B (en) Dry eye treatment process and solution.
ZA977513B (en) Skin tanning compositions and method.
TR27642A (en) Freezing pattern and method in skin ph.
AU1645995A (en) Leather treatment process for leather coloring, leather coloring process performed on leather thereby treated, and leather article produced by the leather coloring process
EP0685219A3 (en) Hair treatment agent and process for its use.
AU3124397A (en) Method and product for promoting hair growth and treating skin conditions
EP0681826A3 (en) Heat-safe hair preparation and method of using same.
PL332579A1 (en) Application of 1-hydroxy-2-pyridinones in treating dermatological infections
GB9218763D0 (en) Hair and skin treatment method
GB9408480D0 (en) Treated natural or artificial hair for use in lengthening or thickening human hair, and methods, processes, apparatus and tools relating thereto
AU5974999A (en) Hair treatment composition, method and use
CA95615S (en) Tanned hide
AU6712394A (en) Microemulsified hair treatment products and methods of making same
HU9903098D0 (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
PL337665A1 (en) (s) 2-methylamine-2-phenyl-n-butyl-3,4,5-trimethoxybezoate and application thereof in treating long-lasting pains
CA2258891A1 (en) Anticonvulsant derivatives useful in treating psoriasis
GB9015369D0 (en) Amidated fibrinolytic enzymes and their precursors,and processes for their preparation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed